TD Cowen initiated coverage of MBX Biosciences (MBX) with a Buy rating and no price target The firm believes the company’s Prostate Secretory Protein platform is supported by “world-class chemistry with strong management.” Canvuparatide exceeded high expectations with the recent Phase II hypoparathyroidism data, which provides conviction in Phase III success, the analyst tells investors in a research note. TD estimates peak sales of $2B.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide
- MBX Biosciences’ New Study on Obesity Treatment: A Potential Game-Changer?
- MBX Biosciences’ Hypoparathyroidism Study: A Potential Game Changer?
- 3 Best Stocks to Buy Now, 10/16/2025, According to Top Analysts
- MBX Biosciences initiated with a Buy at Truist